^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    eflornithine

    Associations

    News

    Trials
    Company:
    Orbus Therap
    Drug class:
    Ornithine decarboxylase inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma (clinicaltrials.gov)
    P1, N=66, Recruiting, Orbus Therapeutics, Inc. | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    temozolomide • eflornithine
    over1year
    Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1, N=66, Recruiting, Orbus Therapeutics, Inc. | Phase classification: P1b --> P1
    Phase classification
    |
    IDH wild-type
    |
    temozolomide • eflornithine
    over2years
    Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1b, N=60, Recruiting, Orbus Therapeutics, Inc.
    New P1 trial
    |
    IDH wild-type
    |
    temozolomide • eflornithine